Borrelia: infected or not infected?
The new C6® technology for a more effective diagnostic testing for canine Borreliosis
Due to the variable clinical picture of the infection with Borrelia burgdorferi, diagnostic testing for canine borreliosis is still a challenge for veterinarians. Tests may either directly detect the organism or measure the anti-bodies to Borrelia. The traditional two-tiered approach consists of the measurement of antibodies to the whole Borrelia burgdorferi organism (whole-cell antibody testing/ELISA) combined with further characterizing of positive dogs using a Western Blot.
The C6® ELISA technology sets new standards
The qualitative C6® test is a screening tool that enables veterinarians to diagnose active Borrelia infection and at the same time distinguish natural exposure from vaccination. In addition, the quantitative Quant C6® ELISA helps to decide on a therapeutic plan and to monitor your treatment choice.
C6® technology or traditional two-tiered diagnostics?
For the reasons mentioned above, the traditional two-tiered diagnostic approach should be chosen for all animals treated with antibiotics active against Borrelia (e.g. doxycycline, amoxicillin) within the previous months. An antibiotic therapy initiated some weeks prior to blood sampling does not influence C6® test results. Animals with clinically manifest borreliosis may have positive C6® antibody levels despite antibiotic treatment. In vaccinated animals, C6® determination is the test of choice, because vaccination does not produce an increase of C6® antibodies.
What is C6®?
The C6® technology is based on recognition of antibodies to the C6® peptide, a highly specific conserved immunodominant portion of the VIsE outer-surface antigen of Borrelia burgdorferi. The C6®technology enables identification of a specific antibody produced during active infection with the organism.
Quant C6® – a quantitative antibody test
- Borrelia Quant C6® Antibody Test (ELISA) Material: 1 mL serum
C6® identifies early infection
The C6® antibody test yields Borrelia-positive results only if live vital Borrelia organisms are detected in the mammal. In most cases, the test is positive as early as 3 weeks after the tick bite.
C6® does not cross-react with other spirochetes (e.g. leptospires) or with vaccine-induced antibodies. This makes it easy to clearly distinguish between vaccination and field infection.
Monitor treatment effectiveness
After successful therapy, C6® antibody levels decline sharply and much faster than the whole-cell antibodies against Borrelia. To assess response to treatment we recommend retesting at 3 to 6 months after initial therapy.
No more chances for borreliosis
Thanks to the innovative C6® technology, antibodies to Borrelia burgdorferi can be reliably detected also in vaccinated dogs.*
*For the reasons mentioned above, the traditional two-tiered diagnostic approach should be chosen for all animals treated with antibiotics active against Borrelia (e.g. doxycycline, amoxicillin) during the previous months. An antibiotic therapy initiated some weeks prior to blood sampling does not influence the C6® test results. Animals with clinically manifest borreliosis may have positive C6® antibody levels despite antibiotic treatment.